STOCK TITAN

Solid Biosciences Inc - SLDB STOCK NEWS

Welcome to our dedicated news page for Solid Biosciences (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Solid Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Solid Biosciences's position in the market.

Rhea-AI Summary
Solid Biosciences Inc. (SLDB) to present at Piper Sandler Healthcare Conference on November 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.17%
Tags
conferences
-
Rhea-AI Summary
Solid Biosciences Inc. (Nasdaq: SLDB) has received FDA clearance for an Investigational New Drug (IND) application for SGT-003, a next-generation gene therapy candidate for Duchenne Muscular Dystrophy (Duchenne). The Phase 1/2 trial, SGT-003-101, will study patients 4 to < 6 years of age with DMD, evaluating safety and tolerability at a dose of 1E14vg/kg. Long-term safety and efficacy will be assessed for 5 years post-treatment. Preclinical data suggests potential benefits for muscular function and durability of benefit in patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.93%
Tags
none
-
Rhea-AI Summary
SLDB: Solid Biosciences to Present at Jefferies London Healthcare Conference on November 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.66%
Tags
conferences
Rhea-AI Summary
Solid Biosciences Inc. (Nasdaq: SLDB) reported financial results for Q3 2023, including an IND submission for SGT-003 gene therapy for Duchenne muscular dystrophy, and the appointment of Dr. Gabriel Brooks as CMO. The company ended Q3 2023 with approximately $142.9 million in cash and investments, with an anticipated cash runway through multiple important pipeline milestones and into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.66%
Tags
-
Rhea-AI Summary
Solid Biosciences appoints Gabriel Brooks, M.D., as Chief Medical Officer, supporting their focus on neuromuscular and cardiac diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
management
-
Rhea-AI Summary
Stoke Therapeutics appoints Ian Smith to its Board of Directors, bringing significant experience in the development of medicines for rare genetic diseases. Smith's expertise and track record in the biotech industry will be valuable as Stoke advances STK-001 for Dravet syndrome. This represents a unique opportunity to develop disease-modifying medicines for challenging diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
management
Rhea-AI Summary
Solid Biosciences Inc. to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
conferences
-
Rhea-AI Summary
Solid Biosciences Inc. CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
conferences
-
Rhea-AI Summary
Solid Biosciences to present at Citi 18th Annual BioPharma Conference on September 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
conferences
Rhea-AI Summary
Solid Biosciences reports financial results for Q2 2023 and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
Solid Biosciences Inc

Nasdaq:SLDB

SLDB Rankings

SLDB Stock Data

391.54M
18.01M
0.79%
75.88%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Charlestown

About SLDB

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.